Content about Tender offer

January 23, 2014

Valeant Pharmaceuticals International on Thursday announced the expiration of the tender offer by a subsidiary of Valeant Pharmaceuticals International to purchase all of the outstanding shares of Solta Medical for $2.92 per share in cash, without interest (less any applicable withholding taxes).

LAVAL, Quebec — Valeant Pharmaceuticals International on Thursday announced the expiration of the tender offer by a subsidiary of Valeant Pharmaceuticals International to purchase all of the outstanding shares of Solta Medical for $2.92 per share in cash, without interest (less any applicable withholding taxes). 

The offer expired at midnight on Jan. 23, 2014. 

January 14, 2014

McKesson may take another bite of the Celesio apple, suggested Sterne Agee analyst Greg Bolan in a note published Monday.

 NASHVILLE, Tenn. — McKesson may take another bite of the Celesio apple, suggested Sterne Agee analyst Greg Bolan in a note published Monday.

January 9, 2014

McKesson Corp. has reached an agreement with Franz Haniel & Cie. GmbH, currently representing a 50.01% stake in Celesio, to sweeten the purchase price for its shareholding in Celesio to EUR 23.50 per share.

SAN FRANCISCO and FRANKFURT, Germany — McKesson Corp. has reached an agreement with Franz Haniel & Cie. GmbH, currently representing a 50.01% stake in Celesio, to sweeten the purchase price for its shareholding in Celesio to EUR 23.50 per share.

Accordingly, the price McKesson is offering to all shareholders of Celesio by way of a voluntary public takeover offer increases to EUR 23.50 per share.

November 25, 2013

The global market research firm Harris Interactive on Monday announced that it has entered into a definitive merger agreement to be acquired by Nielsen Holdings.

ROCHESTER, N.Y. — The global market research firm Harris Interactive on Monday announced that it has entered into a definitive merger agreement to be acquired by Nielsen Holdings. 

December 27, 2012

CVS Caremark has announced the final results of its previously announced cash tender offers commenced on Nov. 26, 2012 of its 6.6% senior notes due 2019 and up to a maximum amount of its 6.125% senior notes due 2016 and 5.75% senior notes due 2017.

WOONSOCKET, R.I. — CVS Caremark has announced the final results of its previously announced cash tender offers commenced on Nov. 26, 2012 of its 6.6% senior notes due 2019 and up to a maximum amount of its 6.125% senior notes due 2016 and 5.75% senior notes due 2017.

The offers expired on Dec. 21, 2012. An aggregate principal amount of about $1.74 billion of notes was tendered.
 

May 11, 2012

GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

LONDON — GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

The drug maker said Thursday that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash, a premium of 81% to HGS's closing share price of $7.17 per share on April 18, the last trading day before HGS publicly disclosed GSK's private offer.

December 8, 2011

CVS Caremark has announced the expiration and final results of its previously announced tender offer for any and all of its $1 billion outstanding 6.302% enhanced capital advantaged preferred securities.

WOONSOCKET, R.I. — CVS Caremark has announced the expiration and final results of its previously announced tender offer for any and all of its $1 billion outstanding 6.302% enhanced capital advantaged preferred securities.

The tender offer commenced on Nov. 29 and expired on Dec. 7.  Based on the final tabulation provided by the information agent for the tender offer, D.F. King & Co., holders of the notes tendered $957.7 million aggregate principal amount of the notes on or prior to the expiration date.

September 6, 2011

Pfizer has completed its initial cash tender offer for all the shares of drug maker Icagen that it doesn't already own, Pfizer said Tuesday.

NEW YORK — Pfizer has completed its initial cash tender offer for all the shares of drug maker Icagen that it doesn't already own, Pfizer said Tuesday.

Pfizer, which already owns an 11% stake in Icagen, announced Thursday that it would acquire a majority stake in the company. As of Friday, when the initial tender offer period expired, about 4.6 million shares of Icagen had been put up for sale; combined with Pfizer's existing stake, this represents about 64% of the North Carolina-based maker of drugs for pain, epilepsy and inflammation.

April 5, 2011

Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.

WHITEHOUSE STATION, N.J. — Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.

March 14, 2011

Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.

FOSTER CITY, Calif. — Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.

Gilead said that TRC seeks to purchase up to 3 million shares of the company at a price of $37.25 per share, or about $111.75 million. The drug maker said it is recommending shareholders reject the bid, stating that the offer is priced below the current market price for Gilead shares and is subject to numerous conditions. As of March 2, TRC's offer price represented approximately a 4.56% discount to the $39.03 closing price of Gilead common stock.

December 14, 2010

Matrixx Initiatives on Tuesday announced that it has entered into a definitive merger agreement to be acquired by affiliates of private equity firm H.I.G. Capital.

SCOTTSDALE, Ariz. — Matrixx Initiatives on Tuesday announced that it has entered into a definitive merger agreement to be acquired by affiliates of private equity firm H.I.G. Capital.

The board of directors of Matrixx unanimously has approved the merger agreement. Under the terms of the merger agreement, affiliates of H.I.G. will commence a tender offer to purchase all of the outstanding shares for approximately $75.2 million.

November 10, 2010

A drug store chain advised shareholders against tendering their shares after being alerted of an...